Results 41 to 50 of about 389,008 (191)

Kostmann disease and other forms of severe congenital neutropenia

open access: yes, 2021
Congenital neutropenia with autosomal recessive inheritance was first described by the Swedish paediatrician Rolf Kostmann who coined the term ‘infantile genetic agranulocytosis’. The condition is now commonly referred to as Kostmann disease.
Göran Carlsson   +19 more
core   +1 more source

Granulopoiesis in severe congenital neutropenia [PDF]

open access: yesBlood, 1976
The pathogenesis of the granulopoietic failure in three children with severe congenital neutropenia was studied. Mature neutrophils were absent from both peripheral blood and bone marrow. Assay of bone marrow granulocyte colony-forming cells (CFU-C) in a methylcellulose tissue culture system using colony-stimulating activity (CSA) from peripheral blood
D, Amato, M H, Freedman, E F, Saunders
openaire   +3 more sources

Generation and characterization of a human iPSC line SANi007-A from a patient with a heterozygous dominant mutation in ELANE

open access: yesStem Cell Research, 2021
Induced pluripotent stem cell (iPSC) line was generated from erythroblasts (EBLs) derived from a patient diagnosed with severe congenital neutropenia, caused by mutations in ELANE (c.614delG).
Cathelijn E.M. Aarts   +6 more
doaj   +1 more source

Elastase-dependent congenital neutropenia

open access: yes, 2023
Congenital neutropenia, which refers to an inherited deficiency in neutrophils, is a rare pathologic condition that affects approximately 0.0001-0.0009% of the general population. While congenital neutropenia can result from mutations in approximately 30
Majewski, Pawel   +3 more
core  

Novel Mutation Detection of an Inflammatory Molecule Elastase ii Gene Encoding Neutrophil Elastase in Kostmann Syndrome

open access: yesEuropean Journal of Inflammation, 2007
Severe congenital neutropenia (SCN), often referred to as Kostmann syndrome, is a rare immune deficiency syndrome diagnosed at or soon after birth, characterized by maturation arrest of myeloid cells at the promyelocyte stage of hematopoiesis.
G. Ahangari   +4 more
doaj   +1 more source

THE EVALUATION OF CONGENITAL NEUTROPENIA PATIENTS

open access: yesHematology, Transfusion and Cell Therapy, 2021
Objective: Congenital neutropenia is a rare disorder. The survival and quality of lives of these patients were improved with avoidance of infections, GCSF usage and appropriate usage of antibiotics in infections.
Nihal Karadaş   +3 more
doaj   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

open access: yesArthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi   +10 more
wiley   +1 more source

Exome Sequencing Uncovers Phenotypic and Genotypic Heterogeneity in 196 Indian Families Evaluated for Autoinflammatory Disorders

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autoinflammatory disorders (AIDs) are a clinically heterogeneous group of inborn errors of immunity primarily caused by dysregulation in the innate immune system. Clinical diagnosis is often challenging due to clinical heterogeneity and the overlapping phenotypes with other inborn errors of immunity and monogenic conditions that mimic AIDs ...
Vaishnavi Ashok Badiger   +28 more
wiley   +1 more source

G6PC3 mutations cause non-syndromic severe congenital neutropenia

open access: yes, 2013
The deficiency of ubiquitously expressed glucose-6-phosphatase (G6PC3) enzyme is known to result in a syndrome characterized by severe congenital neutropenia, prominent superficial venous pattern, congenital heart defects and genito-urinary malformations.
Byers, Helen   +4 more
core   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Home - About - Disclaimer - Privacy